Singapore markets closed

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.6400+0.0100 (+0.61%)
At close: 04:00PM EDT
1.6800 +0.04 (+2.44%)
After hours: 05:12PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Cash flows from operating activities
Net income
-228,340
-234,632
-183,118
-250,219
-204,472
-
Depreciation & amortisation
20,247
20,250
18,020
13,624
4,294
-
Stock-based compensation
42,357
47,084
81,924
62,201
33,261
-
Change in working capital
4,495
3,421
-82,015
4,015
-336
-
Accounts payable
-718
1,464
667
91
-278
-
Other working capital
-160,681
-166,380
-193,831
-191,753
-212,355
-
Other non-cash items
-2,057
-4,653
-6,683
4,624
12,047
-
Net cash provided by operating activities
-159,498
-163,694
-169,555
-126,249
-160,874
-
Cash flows from investing activities
Investments in property, plant and equipment
-1,183
-2,686
-24,276
-65,504
-51,481
-
Purchases of investments
-476,331
-476,880
-406,316
-673,465
-908,357
-
Sales/maturities of investments
651,402
663,614
419,052
617,396
686,322
-
Net cash used for investing activities
173,888
184,048
-11,540
-121,573
-273,516
-
Cash flows from financing activities
Common stock issued
-
0
0
391,802
0
-
Common stock repurchased
-
-
0
0
-16,050
-185
Other financing activities
-464
-457
-461
-
-
-
Net cash used provided by (used for) financing activities
1,839
1,743
10,635
401,244
476,790
-
Net change in cash
16,229
22,097
-170,460
153,422
42,400
-
Cash at beginning of period
109,707
123,834
294,294
140,872
98,472
-
Cash at end of period
125,936
145,931
123,834
294,294
140,872
-
Free cash flow
Operating cash flow
-159,498
-163,694
-169,555
-126,249
-160,874
-
Capital expenditure
-1,183
-2,686
-24,276
-65,504
-51,481
-
Free cash flow
-160,681
-166,380
-193,831
-191,753
-212,355
-